NBP (NovaBridge Biosciences) Non Operating Income: $-1.68 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NBP NovaBridge Biosciences NBP
30 GF Score
Price $1.80
! 2 Warning Signs
View Full Analysis

What is NovaBridge Biosciences Non Operating Income?

NovaBridge Biosciences NBP 30 Non Operating Income is $-1.68 Mil as of Jun. 2026. GuruFocus rates NBP with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. NovaBridge Biosciences's Non Operating Income for the three months ended in Jun. 2026 was $0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.68 Mil.

NovaBridge Biosciences Non Operating Income Related Terms

NovaBridge Biosciences Non Operating Income Historical Data

* Premium members only.

The historical data trend for NovaBridge Biosciences's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBridge Biosciences Non Operating Income Chart

NovaBridge Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only -46.11 -92.98 -42.54 -5.76 -1.68

NovaBridge Biosciences Quarterly Data
Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 -0.19 0.01 -1.75 0.00
NBP
30GF Score
NovaBridge Biosciences NBP
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-1.68 Mil mean?
NovaBridge Biosciences (NBP) has a Non Operating Income of $-1.68 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on NovaBridge Biosciences and its competitors.
Is NovaBridge Biosciences' Non Operating Income too high?
NovaBridge Biosciences' current Non Operating Income is $-1.68 Mil. Overall, NovaBridge Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' Non Operating Income compare to PEPG and DTIL?
NovaBridge Biosciences' Non Operating Income of $-1.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on NovaBridge Biosciences and its competitors. NovaBridge Biosciences's current Non Operating Income is $-1.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
NovaBridge Biosciences (NBP) has a current Non Operating Income of $-1.68 Mil. The current Non Operating Income is $-1.68 Mil. NovaBridge Biosciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For NovaBridge Biosciences (NBP), the current Non Operating Income is $-1.68 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovaBridge Biosciences Business Description

Other Exchanges 0VY:Germany
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
30GF Score

Get the complete analysis for NBP

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price